Business Context and Reporting Period
This Form 8-K was filed by Adagio Therapeutics, Inc. (now identified in the request as Invivyd, Inc.) under Item 8.01, Other Events. The report date was February 18, 2022, and the filing was signed on February 22, 2022. The company’s common stock traded on Nasdaq under the symbol ADGI.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes and Corporate Updates
- On February 18, 2022, the company issued a press release announcing a chief executive officer succession plan.
- On February 22, 2022, the company issued a press release announcing ADG20 development plans and pipeline updates.
- The filing includes those press releases as Exhibits 99.1 and 99.2, but the substantive contents of the releases are not included in the provided filing text.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide clear guidance, clinical-development milestones, regulatory expectations, financial outlook, risk disclosures, contingencies, or details regarding the CEO succession plan or ADG20 pipeline updates.
Important Facts to Verify
- Review Exhibits 99.1 and 99.2 for the identity and timing of the CEO successor, transition terms, and management commentary.
- Verify the detailed ADG20 development plans, pipeline changes, clinical or regulatory milestones, and expected costs or funding requirements.
- Confirm the company’s current corporate name and ticker, as the filing identifies the registrant as Adagio Therapeutics, Inc., while the request identifies Invivyd, Inc.
- Consult the company’s accompanying periodic filings for financial condition, cash runway, liquidity, debt, and risk information.